Cushing's Syndrome Classification and Diagnosis

Introduction to Cushing's Syndrome

• The Endocrine Society recommends that ACTH levels be used to determine whether Cushing's syndrome is ACTH-dependent or ACTH-independent, as ACTH levels are the definitive factor in this distinction 1, 2
• Elevated ACTH levels indicate ACTH-dependent Cushing's syndrome, which can be caused by a pituitary adenoma or an ectopic source, with a sensitivity of 70% and specificity of 100% for diagnosing Cushing's disease when ACTH levels are >29 ng/L 2
• Low or undetectable ACTH levels indicate ACTH-independent Cushing's syndrome, which can be caused by an adrenal source, such as an adrenal adenoma or carcinoma 3

Diagnostic Criteria

• Any ACTH level >5 ng/L is detectable and suggests an ACTH-dependent form of Cushing's syndrome, with a high degree of certainty, as stated by the American Association of Clinical Endocrinologists 2, 4
• An ACTH level >29 ng/L has 70% sensitivity and 100% specificity for diagnosing Cushing's disease, which is a type of ACTH-dependent Cushing's syndrome, according to the Endocrine Society 2

Diagnostic Algorithm

• For ACTH-dependent Cushing's syndrome, further testing is needed to determine the source, including a CRH stimulation test, pituitary MRI, and bilateral inferior petrosal sinus sampling (BIPSS) if necessary, as recommended by the European Society of Endocrinology 2, 1, 4
• For ACTH-independent Cushing's syndrome, an adrenal CT scan is indicated to identify the adrenal lesion(s), and treatment options include laparoscopic adrenalectomy for adrenal adenoma, open adrenalectomy with possible adjuvant therapy for adrenal carcinoma, and medical management or unilateral adrenalectomy for bilateral hyperplasia, according to the National Comprehensive Cancer Network 3

Treatment Implications

• Accurate classification based on ACTH levels is essential for proper diagnosis and treatment planning, and mischaracterization can lead to inappropriate management strategies and poor outcomes, as emphasized by the Endocrine Society 1, 2
• The American Association of Clinical Endocrinologists recommends that treatment for ACTH-dependent ectopic ACTH syndrome include surgical removal of the ectopic tumor when possible, and bilateral adrenalectomy or medical management if unresectable 3
• The National Comprehensive Cancer Network recommends that treatment for ACTH-independent Cushing's syndrome include laparoscopic adrenalectomy for adrenal adenoma, open adrenalectomy with possible adjuvant therapy for adrenal carcinoma, and medical management or unilateral adrenalectomy for bilateral hyperplasia 3

Diagnosing ACTH Dependency in Cushing's Syndrome

Diagnostic Considerations

• Normal ACTH levels with elevated cortisol levels and failed low-dose dexamethasone suppression test (LDDST) could represent either early ACTH-independent Cushing's syndrome (adrenal source) or possible pseudo-Cushing's states that need to be excluded, according to The Lancet Diabetes and Endocrinology 5
• Relying solely on LDDST without measuring ACTH levels can lead to misdiagnosis, as stated by The Lancet Diabetes and Endocrinology 5
• Cyclic Cushing's syndrome can produce inconsistent results, requiring periodic re-evaluation, as noted by The Lancet Diabetes and Endocrinology 5
• Certain conditions, such as severe obesity, can cause false positive results in screening tests, according to The Lancet Diabetes and Endocrinology 5
• Alcoholism can also cause false positive results in screening tests, as reported by The Lancet Diabetes and Endocrinology 5

Diagnostic Algorithm

• For ACTH-Dependent Cushing's, performing pituitary MRI is recommended, as suggested by The Lancet Diabetes and Endocrinology 5
• For ACTH-Independent Cushing's, performing adrenal CT or MRI to identify adrenal lesion(s) is recommended, according to The Lancet Diabetes and Endocrinology 5

Conclusion

• The combination of elevated cortisol, normal ACTH, and failed LDDST suggests ACTH-independent Cushing's syndrome rather than ACTH-dependent disease, and further evaluation with adrenal imaging would be the appropriate next step to identify a potential adrenal source, as stated by The Lancet Diabetes and Endocrinology 5

Diagnostic Approach for Cushing's Disease with Inconclusive MRI and Partial Cortisol Suppression

Understanding the Current Diagnostic Picture

• The patient's LDDST shows >50% suppression of cortisol to a level above the normal cutoff, suggesting Cushing's syndrome is still likely present, with normal cortisol suppression being to <1.8 μg/dL 6
• The >50% suppression pattern is suggestive of Cushing's disease, a pituitary source, rather than ectopic ACTH or adrenal causes 6
• With an inconclusive MRI and suggestive but not definitive LDDST results, further testing is needed to confirm the diagnosis and localize the source 6
• Normal cortisol suppression on LDDST would be to <1.8 μg/dL, and values above this threshold indicate abnormal feedback inhibition consistent with Cushing's syndrome 7

Diagnostic Algorithm for This Scenario

• According to the consensus guidelines, patients with lesions or inconclusive MRI findings should undergo BIPSS to confirm the diagnosis, as it is considered the gold standard test for differentiating between pituitary and ectopic sources of ACTH-dependent Cushing's syndrome 6
• Measuring dexamethasone levels along with cortisol during LDDST can improve test interpretability and rule out abnormal dexamethasone metabolism, as recommended by the Endocrine Society 6

Cushing's Syndrome Diagnosis After Positive Dexamethasone Suppression Test

Diagnostic Approach

• The Endocrine Society recommends measuring plasma ACTH levels to determine if Cushing's syndrome is ACTH-dependent or ACTH-independent in patients with elevated 24-hour urinary cortisol and failed overnight 1mg dexamethasone suppression test 8
• Elevated 24-hour urinary free cortisol is a positive screening test for Cushing's syndrome, as recommended by the Endocrine Society 8
• Failed overnight 1mg dexamethasone suppression test (cortisol >1.8 μg/dL cutoff) is a positive screening test for Cushing's syndrome, as recommended by the Endocrine Society 8
• Severe obesity may cause false positives in screening tests, including dexamethasone suppression testing, according to the Endocrine Society 8
• Uncontrolled diabetes mellitus may cause false positives in screening tests, including dexamethasone suppression testing, according to the Endocrine Society 8

Diagnostic Evaluation

• For ACTH-independent Cushing's syndrome, the Endocrine Society recommends performing adrenal CT or MRI to identify adrenal lesion(s) 8
• For ACTH-dependent Cushing's syndrome, the Endocrine Society recommends performing pituitary MRI 8
• If pituitary adenoma ≥10 mm is found on MRI, the Endocrine Society presumes Cushing's disease 8
• If pituitary adenoma 6-9 mm is found on MRI, the Endocrine Society considers CRH stimulation test 8
• If no adenoma or <6 mm lesion is found on MRI, the Endocrine Society recommends performing bilateral inferior petrosal sinus sampling (BIPSS) 8

Diagnostic Approach to Cushing's Syndrome

Diagnostic Evaluation

• Adrenal CT or MRI is recommended to identify adrenal lesion(s) in patients with ACTH-Independent Cushing's Syndrome, according to The Endocrine Society 9
• Normal cortisol suppression on dexamethasone suppression test is defined as <1.8 μg/dL (50 nmol/L), and values above this threshold indicate abnormal feedback inhibition, as stated by The Endocrine Society 10
• False positive results in screening tests may occur due to rapid absorption/malabsorption of dexamethasone, concomitant treatment with CYP3A4 inducers, increased corticosteroid binding globulin levels from oral estrogens or pregnancy, as reported by The Endocrine Society 10

Potential Pitfalls and Subclinical Cases

• Subclinical Cushing's syndrome (abnormal dexamethasone suppression without overt signs of cortisol excess) may require additional testing and careful clinical correlation, as noted by The Urologic Society 11
• Pseudo-Cushing's states (e.g., depression, alcoholism, obesity) can cause false positive screening results, according to The Endocrine Society 10

Treatment Implications

• For ACTH-independent Cushing's syndrome from adrenal adenoma, laparoscopic adrenalectomy is recommended, as suggested by The Urologic Society 9

Optimal Timing for ACTH Measurement in Pituitary Adenoma Assessment

Diagnostic Algorithm for ACTH Measurement

• Morning (08:00-09:00h) plasma ACTH measurement is the optimal time for initial assessment of pituitary adenomas, particularly for Cushing's disease evaluation 12, 13
• In patients with confirmed hypercortisolism, a morning ACTH level >5 ng/L (>1.1 pmol/L) is detectable in all patients with Cushing's disease 12
• Using a cut-off value of 29 ng/L (6.4 pmol/L), morning ACTH has 70% sensitivity and 100% specificity for diagnosing Cushing's disease in the presence of confirmed hypercortisolism 12, 13
• In ACTH-independent Cushing's syndrome, ACTH is always low and usually undetectable 12

Special Considerations for ACTH Measurement

• For patients with cyclical Cushing's disease, hypercortisolemia must be confirmed immediately prior to diagnostic procedures like bilateral inferior petrosal sinus sampling (BIPSS) to ensure the patient is in an active disease phase 12
• Medical therapy for Cushing's disease (steroidogenesis inhibitors) must be stopped before undertaking BIPSS to enable accurate interpretation of results 12
• For patients with inconclusive MRI findings, BIPSS should be performed to confirm a pituitary source of ACTH excess 12
• During BIPSS, a pituitary source of ACTH excess is confirmed by a central-to-peripheral ACTH ratio ≥2:1 before CRH or desmopressin and ≥3:1 after stimulation 12

Clinical Implications

• For ACTH-dependent Cushing's syndrome with no identified adenoma on pituitary MRI, BIPSS should be offered to confirm a central source of ACTH excess 12
• BIPSS should only be performed in a specialist center with expertise in such testing and by an experienced interventional radiologist 12
• BIPSS may also provide information on tumor lateralization if the inter-petrosal sinus ACTH gradient after CRH or desmopressin stimulation is ≥1.4 between the two sides 12

Timing of ACTH Stimulation Test

Rationale for Morning Testing

• In patients with confirmed Cushing syndrome, a normal or elevated 09:00h plasma ACTH supports the diagnosis of ACTH dependency and Cushing disease 14, 15

Physiological Considerations

• Cortisol follows a diurnal rhythm with highest levels in the morning and lowest at midnight, making morning testing the standard reference point 15
• Morning testing provides better standardization across patients and allows for comparison with established reference ranges 14

Diagnostic Protocol Recommendations

• For diagnosing Cushing syndrome, guidelines recommend measuring morning (09:00h) plasma ACTH to determine if the condition is ACTH-dependent or ACTH-independent 14, 15
• For adrenal incidentalomas, the 1mg dexamethasone suppression test (DST) should be performed with cortisol measured at 8AM following dexamethasone administration at 11PM the previous night 16
• For patients with suspected adrenal insufficiency, morning ACTH stimulation testing provides more reliable baseline cortisol values 17, 18

Special Considerations

• For patients with cyclical Cushing's disease, hypercortisolemia must be confirmed immediately prior to diagnostic procedures to ensure the patient is in an active disease phase 19
• In patients being evaluated for primary aldosteronism, the aldosterone/renin ratio test should be done in the morning after the patient has been out of bed for 2 hours and seated for 5-15 minutes 16
• For patients with suspected immune-related adverse events causing adrenal insufficiency, morning ACTH and cortisol levels should be measured for proper diagnosis 20

Diagnostic Approach for ACTH-Dependent Cushing's Syndrome

Diagnostic Algorithm

• For confirmed ACTH-dependent Cushing's syndrome, pituitary MRI is the recommended next step to identify a potential pituitary adenoma, according to The Endocrine Society 21, 22
• High-quality MRI with thin slices (3T MRI preferred over 1.5T where available) should be performed to maximize detection of small pituitary adenomas, as recommended by The Endocrine Society 21, 23
• If a pituitary adenoma ≥10 mm is detected on MRI, this strongly suggests Cushing's disease (pituitary source), as stated by The Endocrine Society 22

Further Testing if MRI is Inconclusive

• If no adenoma or a lesion <6 mm is found on MRI, bilateral inferior petrosal sinus sampling (BIPSS) should be performed to definitively distinguish between pituitary and ectopic sources of ACTH, according to The Endocrine Society 21, 22
• BIPSS is considered the gold standard for differentiating between pituitary and ectopic ACTH-secreting tumors, with diagnostic criteria of central-to-peripheral ACTH ratio ≥2:1 before CRH stimulation and ≥3:1 after stimulation, as recommended by The Endocrine Society 22
• Prolactin measurement during BIPSS can improve diagnostic accuracy, as stated by The Endocrine Society 21

Additional Testing Considerations

• If suspicion for ectopic ACTH syndrome is high (such as in patients with very high urinary free cortisol and/or profound hypokalemia), a neck-to-pelvis thin-slice CT scan should be performed, according to The Endocrine Society 22
• CRH and desmopressin stimulation testing can be useful in distinguishing between pituitary and ectopic tumors, with increased plasma ACTH and cortisol following administration usually indicating Cushing's disease, as recommended by The Endocrine Society 21, 22
• A non-invasive approach using a combination of CRH and desmopressin stimulation plus MRI, followed by whole-body CT if diagnosis is equivocal, may be considered in some cases, according to The Endocrine Society 21, 22
• For suspected ectopic ACTH-secreting tumors, 68Ga-DOTATATE PET imaging can be useful in localizing neuroendocrine tumors not seen on conventional imaging, as stated by The Endocrine Society 22

Important Clinical Considerations

• BIPSS should preferably be performed in a specialized center due to potential patient risk, as recommended by The Endocrine Society 21, 22
• None of the diagnostic tests reach 100% specificity, and results may be discordant in up to one-third of patients, according to The Endocrine Society 21
• The clinical context and test results should be used together to guide management, as stated by The Endocrine Society 22

Interpretation of CRH Stimulation Test Following Dexamethasone Suppression

Understanding CRH Stimulation Test Results

• With adequate dexamethasone suppression, a CRH stimulation test showing a cortisol rise >38 nmol/L at 15 minutes indicates ACTH-dependent Cushing's disease, according to the Endocrine Society 24, 25
• Adequate dexamethasone absorption and compliance is confirmed by a dex level of 402 ng/mL, eliminating false-positive concerns from inadequate dexamethasone levels, as recommended by the Endocrine Society 24
• Patients with pseudo-Cushing's states, such as those with depression, alcoholism, or obesity, show blunted ACTH responses to CRH, similar to normal individuals, as noted by the Endocrine Society 24, 25
• The Dex-CRH test demonstrates excellent agreement with desmopressin testing when both are performed, providing confirmatory evidence for the diagnosis of Cushing's disease, according to the Endocrine Society 24, 25
• Ectopic ACTH-secreting tumors typically show less robust responses to CRH compared to pituitary adenomas, though some may respond, as reported by the Endocrine Society 24

CRH Test Indication and Performance

Indications for the CRH Test

• The Endocrine Society recommends the CRH test for patients with confirmed ACTH-dependent Cushing's syndrome and an inconclusive or equivocal pituitary MRI, or to distinguish true Cushing's syndrome from pseudo-Cushing's states in patients with mildly elevated screening tests 26, 27
• The CRH test is indicated for patients with ACTH-dependent Cushing's and a pituitary adenoma 6-9mm on MRI, requiring additional testing before surgery or BIPSS 27
• The test is also used to distinguish Cushing's disease from pseudo-Cushing's states in patients with psychiatric disorders, alcoholism, obesity, or PCOS, and mildly abnormal screening test results 26

Performance of the Dex-CRH Test

• The Dex-CRH test is the standard protocol, combining dexamethasone suppression with CRH stimulation to maximize diagnostic accuracy, as recommended by the Endocrine Society 26
• The test involves administering dexamethasone and then CRH, with measurement of plasma dexamethasone, cortisol, and ACTH levels at specific timepoints, with a sensitivity and specificity of 90% and 95% respectively for Cushing's disease 26
• The 15-minute post-CRH timepoint is most diagnostically accurate for both cortisol and ACTH measurements, with a cutoff of cortisol >38 nmol/L indicating Cushing's disease 26

Interpretation and Alternative Tests

• The Endocrine Society recommends measuring plasma dexamethasone concentration at the time of CRH administration to confirm adequate suppression and rule out false-positive results 26
• For cyclic Cushing's disease, the test should be performed immediately after confirming active hypercortisolism with LNSC, DST, or UFC, with a sensitivity and specificity of 95% and 97% respectively 26
• If the Dex-CRH test is inconclusive or unavailable, BIPSS should be performed for definitive localization, as recommended by the Endocrine Society 26, 27

Diagnosis and Management of Cushing Disease

Epidemiology and Diagnosis

• Pituitary adenomas (Cushing disease) account for 75-80% of ACTH-dependent Cushing syndrome cases, making it statistically the most likely diagnosis 28
• The clinical presentation strongly favors pituitary disease over ectopic ACTH syndrome from carcinoid tumors, with pituitary adenomas being the most common cause of Cushing disease 28
• Microadenomas are the most common cause of Cushing disease, accounting for 98% of cases, and are frequently ≤2 mm in diameter 28

Clinical Presentation and Evaluation

• The classic Cushingoid features (central obesity, moon facies, striae) combined with ACTH-dependent hypercortisolism are characteristic of Cushing disease 28
• The presence of a measurable ACTH level rules out adrenal adenoma as the diagnosis, and any detectable ACTH (>5 ng/L) in the setting of confirmed hypercortisolism indicates an ACTH-dependent etiology, according to the Endocrine Society guidelines 28

Inferior Petrosal Sinus Sampling for Cushing's Disease Diagnosis

Introduction to IPSS

• The Endocrine Society recommends bilateral inferior petrosal sinus sampling (IPSS) as the definitive next step to confirm a pituitary source of ACTH excess in patients with biochemical features of Cushing's disease but normal pituitary MRI 29

Diagnostic Challenges and IPSS

• Microadenomas are often ≤2 mm in diameter, making them difficult or impossible to detect even on high-quality MRI, highlighting the need for IPSS in such cases 30
• MRI has only 63% sensitivity for detecting ACTH-secreting pituitary adenomas, meaning it misses approximately one-third of cases, underscoring the importance of IPSS 30

Diagnostic Algorithm

• The American College of Endocrinology suggests that when pituitary MRI is normal or shows a lesion <6 mm, IPSS should be performed to definitively distinguish between pituitary Cushing's disease and ectopic ACTH syndrome 29
• Lesions ≥10 mm on MRI do not require IPSS, as they can proceed to surgery, according to the Endocrine Society guidelines 29

IPSS Diagnostic Criteria

• The central-to-peripheral ACTH ratio of ≥2:1 at baseline or ≥3:1 after CRH or desmopressin stimulation confirms a pituitary source, with a sensitivity of 96-100% and specificity approaching 100% when performed correctly 29, 30

Technical Considerations for IPSS

• IPSS must be performed at a specialized center by an experienced interventional radiologist, with a successful bilateral cannulation rate should be >85% in experienced hands, as per the Society of Interventional Radiology 29
• Measuring prolactin levels simultaneously from the petrosal sinuses can confirm adequate venous efflux and improve diagnostic accuracy, as recommended by the Endocrine Society 29

ACTH Specimen Collection and Interpretation Guidelines

Introduction to ACTH Measurement

• The American College of Endocrinology recommends morning collection (08:00-09:00h) for accurate diagnostic interpretation of serum ACTH, as ACTH follows a circadian rhythm with peak levels in the morning and nadir at midnight 31
• The Endocrine Society suggests that no guideline or consensus statement recommends fasting for ACTH measurement, as ACTH levels are determined by the hypothalamic-pituitary-adrenal axis feedback mechanisms, not by nutritional status 31, 32

Diagnostic Thresholds and Timing

• The established diagnostic cutoffs for ACTH (>5 pg/mL for ACTH-dependent disease, >29 pg/mL for Cushing's disease) are based on morning measurements, and afternoon ACTH measurements are unreliable because levels are physiologically lower and do not correspond to established diagnostic thresholds 32

Practical Considerations for ACTH Measurement

• The European Society of Endocrinology recommends that patient does NOT need to be fasting for ACTH measurement, and ensure patient is not on exogenous steroids, as these suppress ACTH and confound interpretation 31

Primary Physiological Difference Between Cushing's Disease and Cushing's Syndrome

Defining the Distinction

• Cushing's syndrome encompasses all causes of chronic hypercortisolism, and Cushing's disease specifically refers to ACTH-dependent hypercortisolism caused by a pituitary corticotroph adenoma, representing 75-80% of endogenous Cushing's syndrome cases in children/adolescents and 49-71% in adults 33

Physiological Mechanism

• Cushing's disease is ACTH-dependent, with normal or elevated plasma ACTH levels driving bilateral adrenal cortisol overproduction, and originates from pituitary microadenomas (98% of pediatric cases, frequently ≤2 mm diameter) 33
• The Endocrine Society recommends that Cushing's disease be distinguished from other forms of Cushing's syndrome based on ACTH dependency and anatomical source 33

Diagnostic Implications

• Morning plasma ACTH >5 ng/L indicates ACTH-dependent disease, pointing toward either pituitary or ectopic sources, according to the American Association of Clinical Endocrinologists 33

Cushing's Disease Diagnosis and Evaluation

Pathophysiologic Basis

• The normal circadian rhythm of cortisol is lost in Cushing's disease, but morning levels remain elevated rather than suppressed, according to the Endocrine Society guidelines 34

Diagnostic Considerations

• Do not confuse ACTH-dependent with ACTH-independent Cushing's syndrome - only in adrenal adenomas (ACTH-independent) would you see suppressed ACTH and elevated cortisol, as noted by the National Comprehensive Cancer Network 35

Diagnostic and Prognostic Indicators for Pituitary Macroadenoma in Cushing’s Syndrome

Confirmatory Testing in Obese Patients

• Repeated (2–3) midnight salivary cortisol measurements are recommended to confirm loss of the normal circadian rhythm; this approach is more specific than a single measurement in patients with severe obesity. 36, 37

Prognostic Factors Affecting Surgical Outcomes

• Larger tumor size (e.g., macroadenomas ≥10 mm) is an unfavorable prognostic indicator for achieving surgical cure in Cushing’s disease. 36

Screening and Monitoring of Hypercortisolism

Diagnostic Screening Tests

• 24‑hour urinary free cortisol, the 1‑mg dexamethasone suppression test, and late‑night salivary cortisol are recommended as initial screening tools because they detect hypercortisolism regardless of its underlying cause (e.g., neoplastic or physiologic) 38.

Follow‑up and Resolution of Mild Hypercortisolism

• In patients with mild hypercortisolism, serial monitoring over a period of 3–6 months can demonstrate spontaneous resolution when the precipitating non‑neoplastic condition (such as alcohol use disorder, renal impairment, or severe psychiatric illness) is adequately treated 38.

Bilateral Inferior Petrosal Sinus Sampling (BIPSS) for Diagnosing Cushing Disease

Diagnostic Accuracy of BIPSS

• BIPSS is regarded as the gold‑standard test for distinguishing pituitary Cushing’s disease from ectopic ACTH secretion when pituitary MRI is inconclusive; it demonstrates a sensitivity of 96–100 % and a specificity approaching 100 %【39】.

Interpretation Criteria

• A central‑to‑peripheral ACTH ratio ≥ 2 : 1 at baseline, or ≥ 3 : 1 after CRH or desmopressin stimulation, confirms a pituitary source with sensitivity 96–100 % and specificity near 100 %【39】.
• An inter‑petrosal sinus ACTH gradient ≥ 1.4 after stimulation may suggest lateralization of the tumor, but concordance with surgical findings ranges only from 58 % to 87.5 %【39】.

ACTH Threshold Supporting Pituitary Origin

• A morning plasma ACTH level > 29 ng/L (>6.4 pmol/L) provides 70 % sensitivity and 100 % specificity for diagnosing pituitary Cushing’s disease specifically【39】.

Imaging Context Requiring BIPSS

• Pituitary MRI detects ACTH‑secreting adenomas with a sensitivity of ≈ 63 %; when MRI shows no lesion or a lesion < 6 mm, BIPSS is mandatory to differentiate pituitary from ectopic ACTH sources【39】.

Procedural Prerequisites

• Active hypercortisolism must be confirmed on the same morning before performing BIPSS to ensure patients with cyclic disease are in an active phase【39】.
• All steroidogenesis‑inhibiting medications must be discontinued prior to BIPSS, with wash‑out periods tailored to each drug’s half‑life【39】.

Operational Requirements

• BIPSS should be performed only in specialized centers staffed by interventional radiologists experienced in the procedure for adult patients, as diagnostic reliability and complication rates are highly operator‑dependent【39】.

Diagnostic Approach to ACTH‑Secreting Pituitary Adenoma with Mild Hyperprolactinemia

Imaging Strategy

• Obtain a high‑resolution 3‑Tesla pituitary MRI with thin slices and gadolinium contrast to maximize detection of microadenomas in patients with suspected ACTH‑dependent Cushing’s disease. 40
• If the MRI reveals a lesion ≥10 mm, proceed directly to transsphenoidal surgery without further endocrine testing. 40
• When a lesion measuring 6–9 mm is identified, perform a CRH or desmopressin stimulation test; a robust ACTH and cortisol rise (sensitivity > 70 %) supports a pituitary source. 40

Inferior Petrosal Sinus Sampling (BIPSS)

• BIPSS is mandatory when MRI shows no adenoma or a lesion <6 mm to differentiate pituitary from ectopic ACTH secretion; it has 96–100 % sensitivity and near‑100 % specificity. 40
• Diagnostic criteria: central‑to‑peripheral ACTH ratio ≥ 2:1 at baseline or ≥ 3:1 after CRH/desmopressin stimulation. 40
• BIPSS should be performed only in specialized centers by experienced interventional radiologists, with confirmation of active hypercortisolism on the morning of the procedure and appropriate wash‑out of steroidogenesis inhibitors. [40][41]
• Simultaneous prolactin measurement from petrosal sinuses confirms adequate catheter placement. 40
• An inter‑petrosal ACTH gradient ≥ 1.4 after stimulation may indicate tumor lateralization, correlating with surgical findings in 58–87.5 % of cases. 41

Interpretation of Mild Hyperprolactinemia

• Mild prolactin elevation (typically < 100 ng/mL) in the setting of a pituitary mass most often reflects a “stalk effect” caused by compression of dopaminergic inhibition. 42
• Macroprolactinemia accounts for 10–40 % of hyperprolactinemia cases; testing for macroprolactin is advisable when the patient lacks clinical signs of prolactin excess. 42
• An elevated prolactin level alone does not indicate a prolactinoma in patients with confirmed ACTH‑dependent Cushing’s disease; true prolactinomas usually present with prolactin concentrations > 100–200 ng/mL (often > 1000 ng/mL for macroadenomas) and suppressed ACTH. 42

Management of Untreated Cushing’s Disease

• Delayed diagnosis increases morbidity and mortality from cardiovascular disease, infections, and metabolic complications; therefore, the diagnostic work‑up should be pursued expeditiously. 40

Consideration of Ectopic ACTH Syndrome

• Although pituitary sources account for 75–80 % of ACTH‑dependent Cushing’s disease, ectopic ACTH secretion should be entertained when clinical features such as rapid symptom onset are present. 40
• If BIPSS indicates a peripheral source (central‑to‑peripheral ACTH ratio < 2:1 baseline or < 3:1 after stimulation), obtain neck‑to‑pelvis thin‑slice CT and consider ⁶⁸Ga‑DOTATATE PET imaging to localize neuroendocrine tumors. 40

Monitoring During Diagnostic Work‑up

• While awaiting definitive treatment, closely monitor blood pressure, glucose, and electrolytes; initiate steroidogenesis inhibitors (e.g., ketoconazole, metyrapone) in cases of severe hypercortisolism with complications. 40
• Screen for and treat common Cushing‑related complications, including hypertension, diabetes, infections, and osteoporosis. 40

Ectopic ACTH Syndrome: Tumor Sources and Prevalence

Epidemiology of Pulmonary Carcinoid Tumors

• Up to 40 % of patients with ectopic ACTH syndrome have pulmonary carcinoid tumors, making this tumor type the most common source of ectopic ACTH secretion. 43

Spectrum of Tumors Associated with Ectopic ACTH

*Frequency descriptors are taken from the cited source; exact percentages are not provided.

• The most prevalent tumors causing ectopic ACTH secretion include bronchial carcinoid tumors (most common), small‑cell lung carcinoma, pancreatic neuroendocrine tumors, thymic carcinoids, medullary thyroid carcinoma, and pheochromocytomas. 43

Diagnostic Approach to ACTH‑Dependent Cushing’s Syndrome

Differential Diagnosis Based on Biochemistry

• In patients with concurrent elevation of ACTH and cortisol, the differential diagnosis is limited to a pituitary corticotroph adenoma (Cushing’s disease) or ectopic ACTH secretion 44.

Clinical Clues Suggesting Ectopic ACTH

• Marked hypokalemia is more frequently observed in ectopic ACTH secretion because extremely high cortisol levels overwhelm 11β‑HSD2, producing a mineralocorticoid effect 44.

Imaging Strategies

Pituitary MRI

• The recommended initial imaging study is a high‑resolution 3‑Tesla pituitary MRI with thin slices and gadolinium contrast to detect a corticotroph adenoma 44.

Whole‑Body Evaluation for Suspected Ectopic Sources

• When ectopic ACTH secretion is suspected, a neck‑to‑pelvis thin‑slice CT scan should be performed to locate potential neuroendocrine tumors 44.
• If CT is negative, ⁶⁸Ga‑DOTATATE PET imaging can identify approximately 65 % of ectopic ACTH‑secreting neuroendocrine tumors not seen on conventional imaging 44.

Functional Testing

CRH / Desmopressin Stimulation for Small Pituitary Lesions

• For pituitary lesions measuring 6–9 mm, CRH or desmopressin stimulation is advised; a cortisol increase >38 nmol/L at 15 minutes (with a corresponding ACTH rise) supports a pituitary source and provides >70 % sensitivity 44.

Bilateral Inferior Petrosal Sinus Sampling (BIPSS)

• In the absence of a visible adenoma or when lesions are <6 mm, BIPSS is mandatory, offering 96–100 % sensitivity and near‑100 % specificity for distinguishing pituitary from ectopic ACTH secretion 44.
• Diagnostic criteria: a central‑to‑peripheral ACTH ratio ≥2:1 at baseline or ≥3:1 after CRH/desmopressin stimulation confirms a pituitary origin 44.

Epidemiology of Ectopic ACTH Sources

• Pulmonary carcinoid tumors account for up to 40 % of ectopic ACTH cases, making them the most common ectopic source 45.

Limitations of Diagnostic Tests

• No single test achieves 100 % specificity; discordant results occur in up to one‑third of patients, necessitating integration of clinical, biochemical, and imaging data for final diagnosis 44.

Imaging and Management Recommendations for Pituitary Microadenomas

High‑Resolution Pituitary MRI

• The Endocrine Society (as reported in The Lancet Diabetes & Endocrinology, 2021) recommends obtaining a high‑resolution 3‑Tesla pituitary MRI with 1 mm thin slices and gadolinium contrast to accurately characterize microadenomas as small as 3 mm. 46

Cushing’s Disease Biochemical Workup

• According to the same guideline, clinicians should avoid performing Cushing’s disease screening tests (e.g., low‑dose dexamethasone suppression test, 24‑hour urinary free cortisol, late‑night salivary cortisol) when the patient’s cortisol and ACTH levels do not indicate hypercortisolism. 46

Relationship Between Tumor Size and Hormone Secretion

• The guideline emphasizes that tumor size does not predict hormone output; even microadenomas measuring ~2 mm can produce clinically significant ACTH excess and cause Cushing’s disease. However, in patients lacking biochemical evidence of hypercortisolism, such a scenario is unlikely. 46

Diagnostic Evaluation of Hypercortisolism with ACTH Assessment

ACTH Level Interpretation

Pituitary Imaging Performance

Dynamic Testing for Pituitary Source

Bilateral Inferior Petrosal Sinus Sampling (BIPSS)

Diagnostic Recommendations for ACTH‑Dependent Cushing’s Disease (Cited Evidence)

High‑Dose Dexamethasone Suppression Testing (HDDST)

• HDDST has low overall accuracy for distinguishing pituitary from ectopic ACTH sources, with discordant results in up to one‑third of patients. 48

• Because of its limited diagnostic utility, HDDST should not be used as the primary test for evaluating suspected pituitary microadenomas. 48

Pituitary Magnetic Resonance Imaging (MRI)

• High‑resolution 3‑Tesla pituitary MRI detects ACTH‑secreting adenomas with only ~63 % sensitivity; roughly one‑third of scans remain negative even in confirmed Cushing’s disease. 48

• Tumor size does not correlate with the severity of hypercortisolism; very small microadenomas can produce severe disease. 48

Bilateral Inferior Petrosal Sinus Sampling (BIPSS)

• BIPSS is the gold‑standard for differentiating pituitary from ectopic ACTH secretion when imaging is inconclusive, achieving 96–100 % sensitivity and near‑100 % specificity. 48

• Diagnostic criteria: a central‑to‑peripheral ACTH ratio ≥ 2:1 at baseline or ≥ 3:1 after CRH/desmopressin stimulation confirms a pituitary source. 48

• BIPSS should be performed only in specialized centers with experienced interventional radiologists. 48

• When MRI shows no lesion or a lesion < 6 mm, BIPSS is mandatory because approximately one‑third of Cushing’s disease cases have negative MRI. 48

CRH/Desmopressin Stimulation Testing

• In ACTH‑dependent disease, a rise in plasma ACTH and cortisol after CRH or desmopressin administration typically indicates pituitary Cushing’s disease rather than ectopic ACTH syndrome. 48

• Mechanistic basis: pituitary corticotroph adenomas retain glucocorticoid receptors and overexpress V2, V1b, and CRH receptors, whereas most ectopic ACTH‑secreting tumors lack these receptors. 48

• Limitation: well‑differentiated neuroendocrine tumors may also express these receptors, potentially causing false‑positive stimulation results. 48

Timing and Fasting Requirements for ACTH Testing

Baseline ACTH Measurement

• Morning blood collection between 08:00 – 09:00 h is essential for accurate interpretation of ACTH levels because the hormone follows a circadian rhythm with peak concentrations in the early morning; fasting is not required. 49

ACTH Stimulation (Cosyntropin) Test

• Guidelines for the ACTH stimulation test recommend performing the test in the morning (around 08:00 h) to align with peak endogenous ACTH, but they do not mandate fasting before the procedure. 50, 51, 52